Literature DB >> 8271019

Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage.

Y Hirashima1, S Endo, T Ohmori, R Kato, A Takaku.   

Abstract

The authors studied the sequential changes in platelet-activating factor (PAF) and PAF acetylhydrolase in the cerebrospinal fluid (CSF) of patients with subarachnoid hemorrhage (SAH). Levels of PAF in CSF showed a gradual increase after the onset of SAH, with a subsequent decrease. The PAF concentration between 5 and 9 days after SAH was greater in patients with cerebral infarction due to vasospasm than in patients without infarction. Conversely, PAF acetylhydrolase activity decreased gradually after SAH, then increased. The enzyme activity for the same period was smaller in patients with cerebral infarction than in patients without infarction. The distribution of the days of maximum PAF concentration and minimum PAF acetylhydrolase activity did not differ significantly between the two groups. The CSF as a source of PAF acetylhydrolase activity gave an apparent Michaelis constant value of 90.8 microM and a maximum velocity of 0.2 nmol/min/mg. The optimum pH level for the PAF acetylhydrolase activity obtained from CSF was 6.5. The enzyme activity of CSF increased, depending on the incubation temperature, ranging from 25 degrees to 45 degrees C. Ethylene-glycol tetra-acetic acid (1 mM) was found to inhibit PAF acetylhydrolase activity in CSF obtained from patients with SAH. Unaltered PAF acetylhydrolase activity was inhibited by adding an aliquot of CSF and minimum PAF acetylhydrolase activity decreased following SAH. Two peaks of inhibitory activity were detected on Sephacryl S-200 HR gel filtration: one was eluted in void volume and the other with an apparent molecular mass of 13 kD. The inhibitory activity was very labile and was lost completely within 3 days of incubation at 4 degrees C. The regulation of the PAF concentration in the CSF of SAH patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8271019     DOI: 10.3171/jns.1994.80.1.0031

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

Review 1.  Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke.

Authors:  Cameron Rink; Savita Khanna
Journal:  Antioxid Redox Signal       Date:  2010-12-04       Impact factor: 8.401

Review 2.  Structural and (patho)physiological diversity of PAF.

Authors:  R N Pinckard; D S Woodard; H J Showell; M J Conklyn; M J Novak; L M McManus
Journal:  Clin Rev Allergy       Date:  1994

Review 3.  Metabolic processing of PAF.

Authors:  F Snyder
Journal:  Clin Rev Allergy       Date:  1994

Review 4.  Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a systematic review.

Authors:  Jacoline Boluijt; Joost C M Meijers; Gabriel J E Rinkel; Mervyn D I Vergouwen
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-18       Impact factor: 6.200

5.  Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.

Authors:  Takuya Akai; Kenji Niiya; Nobuo Sakuragawa; Hideaki Iizuka; Shunro Endo
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

6.  Platelet-activating factor (PAF) and the development of chronic subdural haematoma.

Authors:  Y Hirasima; S Endo; R Kato; T Ohmori; T Nagahori; M Nishijima; K Karasawa; S Nojima; A Takaku
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

7.  Topical application of dexamethasone to prevent cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study.

Authors:  Luo Fei; Filimon Golwa
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

8.  Platelet-activating factor and antiphospholipid antibodies in subarachnoid haemorrhage.

Authors:  Y Hirashima; S Endo; M Kurimoto; E Tsukamoto; A Takaku
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.